Our study demonstrates a significant increase in CD8 + memory T cell tumour infiltration in response to the combination of anti-PD-1 and anti-TIGIT, especially after the second dose, where the memory T cell population reaches its highest level. Here, PDCD1 is linked to neoplasm.